Meeting
2019 ASCO Annual Meeting
Radiological response patterns in the phase 2 STELLAR trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma (MPM).
Authors
Federica Grosso
SS Antonio e Biagio Hospital, Department of Oncology, Alessandria, Italy
Federica Grosso , Giovanni Luca Ceresoli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Clinical Trial Registration Number
NCT02397928
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8551)
DOI
10.1200/JCO.2019.37.15_suppl.8551
Abstract #
8551
Poster Bd #
307
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.
First Author: Gerard Zalcman
Poster
2023 ASCO Annual Meeting
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
First Author: Patrick M. Forde
Poster
2022 ASCO Annual Meeting
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
First Author: Patrick M. Forde
Poster
2021 ASCO Annual Meeting
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
First Author: Patrick M. Forde